What is Nektar Therapeutics's gross unrealized gains?

Nektar Therapeutics (NKTR) reported gross unrealized gains of $3K in Q1 2026.

Nektar Therapeutics NKTR Gross Unrealized Gains

Gross Unrealized Gains at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

Arcus BiosciencesRCUS

——

Viridian Therapeutics, Inc.VRDN

——

Spyre Therapeutics, Inc.SYRE

——

Nuvation BioNUVB

——

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's gross unrealized gains?: Nektar Therapeutics (NKTR) reported gross unrealized gains of $3K in Q1 2026.